Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma

Cancer Research

Volumn 61, Issue 17, 2001, Pages 6406-6412

  Sharma, Sherven ^a   Stolina, Marina ^a   Zhu, Li ^a   Lin, Ying ^a   Batra, Raj ^a   Huang, Min ^a   Strieter, Robert ^a   Dubinett, Steven M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; MONOKINE; SECONDARY LYMPHOID ORGAN CHEMOKINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AXILLARY LYMPH NODE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EXPERIMENTAL NEOPLASM; IN VITRO STUDY; LUNG ALVEOLUS CELL CARCINOMA; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40; SPLEEN CELL; T LYMPHOCYTE; TUMOR LOCALIZATION;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CHEMOKINES; CHEMOKINES, CC; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; LUNG NEOPLASMS; LYMPH NODES; LYMPHOKINES; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035417890     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Role of bone marrow-derived cells in presenting MHC class 1-restricted tumor antigens
2. Identification of human cancers deficient in antigen processing
3. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Upregulation of interleukin 10 and down-regulation of interleukin 12 production
4. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function
5. Renal cell carcinoma-derived gangliosides suppress nuclear factor-κB activation in T cells
6. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines
7. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
8. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
9. Cutting edge: Physical interaction between dendritic cells and tumor cells result in an immunogen that induces protective and therapeutic tumor rejection
10. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication
11. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3
12. Human chemokines: An update
13. Chemokine receptors in lymphoid organ homeostasis
14. IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo
15. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma
16. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 β are potent chemoattractants for in vitro- and in vivo-derived dendritic cells
17. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation
18. Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties
19. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
20. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3β receptor CCR7
21. Cutting edge: Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes
22. A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells
23. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs
24. Chemotactic response toward chemokines and its regulation by transforming growth factor-β1 of murine bone marrow hematopoietic progenitor cell-derived different subset of dendritic cells
25. Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells
26. Identification and characterization of a novel β chemokine containing six conserved cysteines
27. Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension
28. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lyraphocytes and mapped to chromosome 9p13
29. Identification of a new mouse β-chemokine, thymus-derived chemotactic agent 4. With activity on T lymphocytes and mesangial cells
30. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCRT
31. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo
32. Dendritic cells and the control of immunity
33. Cyclin-dependent kinase inhibitor expression in pulmonary clara cells transformed with SV40 large t antigen in transgenic mice
34. Multi-component gene therapy vaccines for lung cancer: Effective eradication of established murine tumors in vivo with interleukin 7/herpes thymidine kinase-transduced autologous tumor and ex vivo-activated dendritic cells
35. Interleukin-8 gene expression by a pulmonary epithelial cell line
36. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production: Role of tumor-derived IL-10. TGF-β and prostaglandin E2
37. CD8 T cell clones inhibit autitumor T cell function by secreting IL-10
38. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
39. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells
40. Decreased antigen presentation by dendritic cells in patients with breast cancer
41. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
42. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms
43. The murine CC chemokine, 6Ckine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model
44. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
45. Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients
46. Transforming growth factor β1 induces angiogenesis in vivo with a threshold pattern
47. The role of vascular endothelial growth factor in pathological angiogenesis
48. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
49. Interleukin 10 gene transfer activates interferon γ and the interferon γ inducible genes Gbp-1/Mag-1 and Mig-1 in mammary tumors
50. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site
51. Specific inhibition of cyclooxygenase 2 restores antitumor immunity by altering the balance of IL-10 and IL-12 synthesis
52. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
53. Interleukin-12: A cytokine at the interface of inflammation and immunity
54. Interleukin-12, dendritic cells and the initiation of host-protective mechanisms against Toxoplasma gondii
55. Immunomodulatory functions and molecular regulations of IL-12
56. Inhibition of angiogenesis in vivo by interleukin 12
57. Chemokine receptor specific for IP-10 and Mig: Structure, function and expression in activated T lymphocytes
58. Antitumor and antimetastatic activity of inturleukin 12 against murine tumors
59. Interferonγ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases
60. Mig, the monokine induced by interferon-g, promotes tumor necrosis in vivo
61. Interferon γ-inducible protein 10 (IP-10). A member of the C-X-C chemokine family, is an inhibitor of angiogenesis
62. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
63. Inhibition of lung cancer growth by the novel chemokine 6C-kine
64. Mig and IP-10: CXC chemokines that target lymphocytes
65. Examining the immune response in sentinel lymph nodes of mice and men